Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2019 | Recent immunotherapy advances in RCC

David McDermott • 15 Feb 2019
GU Cancers 2019
Genitourinary Cancer Kidney Cancer Axitinib Checkpoint Inhibitors Ipilimumab Nivolumab Pembrolizumab
KEYNOTE-426 KEYNOTE-427

Prof. David McDermott, MD, of Beth Israel Deaconess Medical Center, Boston, MA, discusses novel treatments in renal cell carcinoma (RCC). At 2019 Genitourinary Cancers Symposium, held in San Francisco, CA, Prof. McDermott focusses on PD1 blockade studies such as KEYNOTE-426 (NCT02853331), where pembrolizumab is combined with axitinib, or KEYNOTE-427 (NCT02853344), where pembrolizumab is used as monotherapy in untreated RCC. Prof. McDermott moves on to explain that patients with tumour PDL-1 expression have enhanced response to such treatment.

More from David McDermott

1:30
RCC treatment: future remarks
David McDermott • 15 Feb 2019
1:54
CheckMate 214 trial in RCC updates
David McDermott • 15 Feb 2019

Related Videos

10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
3:07
Serum thymidine kinase 1 as a predicative biomarker in prostate cancer
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals